Gilead’s Veklury wins expanded FDA nod for moderate COVID-19 patients despite mixed data

Amid daily headlines about COVID-19 vaccines and trends, Gilead’s Veklury, also known as remdesivir, remains the only antiviral drug authorized to treat the illness. With a new move from the FDA, the medicine’s emergency green light is a little broader—despite some lingering questions about its efficacy. Under the expanded emergency use authorization (EUA), all hospitalized… Read More: Gilead’s Veklury wins expanded FDA nod for moderate COVID-19 patients… »

ESC: Merck’s Steglatro shows limited promise with heart failure hospitalization data

Late to the party against its SGLT2 diabetes rivals, Merck & Co.’s Steglatro has also tracked way behind in the class’ growing presence in heart failure. Now, the drugmaker has posted new data showing Steglatro could, in fact, show benefits in that indication—but it’s a limited window into the future. Steglatro cut heart failure patients’ risk… Read More: ESC: Merck’s Steglatro shows limited promise with heart failure hospitalization… »